Research progress of selective serotonin reuptake inhibitor in treatment of adolescent depression
-
摘要:
近年来，青少年抑郁症的发病率呈逐年升高趋势，严重损害青少年的身心健康，使其学业、社交、家庭等社会功能受损，甚至发生自伤、自杀等不良事件，给患者家庭和社会带来了沉重负担。药物治疗是青少年抑郁症的主要治疗方式，其中选择性五羟色胺再摄取抑制剂(SSRI)使用最为广泛。SSRI对青少年抑郁症具有良好的疗效和耐受性，然而临床中普遍存在超说明书用药、不良反应较为常见等问题，且SSRI与青少年抑郁症自杀风险的相关性仍未阐明。本文总结了SSRI治疗青少年抑郁症的相关内容，以期为临床医师制订青少年抑郁症的用药方案提供参考。
-
关键词:
- 选择性五羟色胺再摄取抑制剂 /
- 青少年 /
- 抑郁症 /
- 自杀 /
- 不良反应
Abstract:In recent years, the incidence of depression in adolescents has been increasing year by year, resulting in impairment of their academic, social, family and other social functions, and even adverse events such as self-injury and suicide, which seriously damages the physical and mental health of adolescents and brings a heavy burden to families and society. Pharmacotherapy is the main treatment modality for adolescent depression, among which selective serotonin reuptake inhibitor (SSRI) is the most widely used, and it has better efficacy and tolerability in adolescent depression. However, there are widespread clinical problems such as off-label drug use, adverse reactions, and unclear correlation between SSRI and suicide risk of adolescent depression. In this article, we summarized the relevant content of SSRI in the treatment of adolescent depression, aiming to provide a reference for clinicians to develop medication regimens.
-
Keywords:
- selective serotonin reuptake inhibitor /
- adolescents /
- depression /
- suicide /
- adverse reactions
-
-
[1] REN X W, YU S C, DONG W L, et al. Burden of depression in China, 1990-2017: findings from the global burden of disease study 2017[J]. J Affect Disord, 2020, 268: 95-101. doi: 10.1016/j.jad.2020.03.011
[2] SHOREY S, NG E D, WONG C H J. Global prevalence of depression and elevated depressive symptoms among adolescents: a systematic review and meta-analysis[J]. Br J Clin Psychol, 2022, 61(2): 287-305. doi: 10.1111/bjc.12333
[3] PATTON G C, COFFEY C, SAWYER S M, et al. Global patterns of mortality in young people: a systematic analysis of population health data[J]. Lancet, 2009, 374(9693): 881-892. doi: 10.1016/S0140-6736(09)60741-8
[4] LUKMANJI A, PRINGSHEIM T, BULLOCH A G, et al. Antidepressant prescriptions, including tricyclics, continue to increase in Canadian children[J]. J Child Adolesc Psychopharmacol, 2020, 30(6): 381-388. doi: 10.1089/cap.2019.0121
[5] SAITO T, REINES E H, FLOREA I, et al. Management of depression in adolescents in Japan[J]. J Child Adolesc Psychopharmacol, 2019, 29(10): 753-763. doi: 10.1089/cap.2019.0023
[6] 张久平, 成鑫, 张会会, 等. 2 153例儿少精神科住院患者精神疾病分布及药物使用[J]. 四川精神卫生, 2020, 33(5): 440-445. https://www.cnki.com.cn/Article/CJFDTOTAL-WANT202005013.htm [7] 郭小兵, 于红晔, 王虎. 抑郁症患者用药情况调查及抗抑郁药物联合用药的影响因素分析[J]. 新乡医学院学报, 2021, 38(7): 624-630. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX202107005.htm [8] DHARNI A, COATES D. Psychotropic medication profile in a community youth mental health service in Australia[J]. Child Youth Serv Rev, 2018, 90: 8-14. doi: 10.1016/j.childyouth.2018.05.007
[9] WALKUP J T. Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies[J]. Am J Psychiatry, 2017, 174(5): 430-437. doi: 10.1176/appi.ajp.2017.16091059
[10] LI Y F, HUANG J H, HE Y C, et al. The impact of placebo response rates on clinical trial outcome: a systematic review and meta-analysis of antidepressants in children and adolescents with major depressive disorder[J]. J Child Adolesc Psychopharmacol, 2019, 29(9): 712-720. doi: 10.1089/cap.2019.0022
[11] MURPHY S E, CAPITÃO L P, GILES S L C, et al. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action[J]. Lancet Psychiatry, 2021, 8(9): 824-835. doi: 10.1016/S2215-0366(21)00154-1
[12] OVERBERG A, MORTON S, WAGNER E, et al. Toxicity of bupropion overdose compared with selective serotonin reuptake inhibitors[J]. Pediatrics, 2019, 144(2): e20183295. doi: 10.1542/peds.2018-3295
[13] VITIELLO B, SWEDO S. Antidepressant medications in children[J]. N Engl J Med, 2004, 350(15): 1489-1491. doi: 10.1056/NEJMp038248
[14] BOADEN K, TOMLINSON A, CORTESE S, et al. Antidepressants in children and adolescents: meta-review of efficacy, tolerability and suicidality in acute treatment[J]. Front Psychiatry, 2020, 11: 717.
[15] MARCH J S, SILVA S, PETRYCKI S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes[J]. Arch Gen Psychiatry, 2007, 64(10): 1132-1143. doi: 10.1001/archpsyc.64.10.1132
[16] FOSTER S, MOHLER-KUO M. Treating a broader range of depressed adolescents with combined therapy[J]. J Affect Disord, 2018, 241: 417-424. doi: 10.1016/j.jad.2018.08.027
[17] REYAD A A, PLAHA K, GIRGIS E, et al. Fluoxetine in the management of major depressive disorder in children and adolescents: a meta-analysis of randomized controlled trials[J]. Hosp Pharm, 2021, 56(5): 525-531. doi: 10.1177/0018578720925384
[18] CAPITÃO L P, CHAPMAN R, MURPHY S E, et al. A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents[J]. Transl Psychiatry, 2019, 9(1): 30. doi: 10.1038/s41398-018-0332-2
[19] DE LA PEÑA F R, CRUZ-FUENTES C, PALACIOS L, et al. Serum levels of chemokines in adolescents with major depression treated with fluoxetine[J]. World J Psychiatry, 2020, 10(8): 175-186. doi: 10.5498/wjp.v10.i8.175
[20] HETRICK S E, MCKENZIE J E, BAILEY A P, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 5(5): CD013674.
[21] 唐放放, 陶领钢, 周鑫. 舍曲林治疗青少年抑郁症的开放性研究[J]. 中外医疗, 2020, 39(29): 112-114. https://www.cnki.com.cn/Article/CJFDTOTAL-HZZZ202029046.htm [22] MATSUSHIMA Y, TERADA K, KAMEI C, et al. Sertraline inhibits nerve growth factor-induced neurite outgrowth in PC12 cells via a mechanism involving the Sigma-1 receptor[J]. Eur J Pharmacol, 2019, 853: 129-135. doi: 10.1016/j.ejphar.2019.03.032
[23] 王冲, 刘慧敏, 王春芳. 氟伏沙明联合认知行为治疗儿童青少年情绪障碍的疗效[J]. 临床心身疾病杂志, 2016, 22(S1): 370-371. https://www.cnki.com.cn/Article/CJFDTOTAL-JXUY201707112.htm [24] 衣斌. 氟伏沙明联合认知行为治疗儿童青少年情绪障碍的疗效[J]. 中国继续医学教育, 2017, 9(7): 176-177. doi: 10.3969/j.issn.1674-9308.2017.07.095 [25] 何书平. 氟伏沙明结合认知行为治疗青少年情绪障碍的临床作用[J]. 实用中西医结合临床, 2018, 18(4): 104-105. https://www.cnki.com.cn/Article/CJFDTOTAL-SZXL201804054.htm [26] KIM B. Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland[J]. Drug Metab Pers Ther, 2015, 30(3): 147-163.
[27] EUGENE A R. Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors[J]. PeerJ, 2019, 7: e7860. doi: 10.7717/peerj.7860
[28] GUO J C, ZHU X H, BADAWY S, et al. Metabolism and mechanism of human cytochrome P450 enzyme 1A2[J]. Curr Drug Metab, 2021, 22(1): 40-49. doi: 10.2174/1389200221999210101233135
[29] SÁNCHEZ C, BØGESØ K P, EBERT B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer[J]. Psychopharmacology, 2004, 174(2): 163-176.
[30] LI H F, LI T, LI G J, et al. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials[J]. Ann Clin Psychiatry, 2014, 26(4): 281-287.
[31] 颜景祥, 王健, 杜波, 等. 艾司西酞普兰与西酞普兰治疗抑郁症的对照研究[J]. 中国临床药理学杂志, 2012, 28(5): 340-342, 345. doi: 10.3969/j.issn.1001-6821.2012.05.006 [32] CAMPLEMAN S L, BRENT J, PIZON A F, et al. Drug-specific risk of severe QT prolongation following acute drug overdose[J]. Clin Toxicol (Phila), 2020, 58(12): 1326-1334. doi: 10.1080/15563650.2020.1746330
[33] 邹亮, 张新功, 孙丽丽, 等. 草酸艾司西酞普兰与舍曲林分别联合认知行为治疗青少年抑郁症的临床对照研究[J]. 中国医药导报, 2021, 18(13): 141-144. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202113036.htm [34] 王权鸣, 刘永军. 艾司西酞普兰治疗儿童和青少年抑郁症的Meta分析[J]. 中国新药与临床杂志, 2019, 38(6): 372-377. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL201906014.htm [35] STRAWN J R, DOBSON E T, GILES L L. Primary pediatric care psychopharmacology: focus on medications for ADHD, depression, and anxiety[J]. Curr Probl Pediatr Adolesc Health Care, 2017, 47(1): 3-14. doi: 10.1016/j.cppeds.2016.11.008
[36] APTER A, LIPSCHITZ A, FONG R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine[J]. J Child Adolesc Psychopharmacol, 2006, 16(1/2): 77-90.
[37] KOWALSKA M, NOWACZYK J, FIJAŁKOWSKI Ł, et al. Paroxetine-overview of the molecular mechanisms of action[J]. Int J Mol Sci, 2021, 22(4): 1662. doi: 10.3390/ijms22041662
[38] BAHAR M A, KAMP J, BORGSTEEDE S D, et al. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine[J]. Br J Clin Pharmacol, 2018, 84(12): 2704-2715. doi: 10.1111/bcp.13741
[39] DWYER J B, STRINGARIS A, BRENT D A, et al. Annual Research Review: defining and treating pediatric treatment-resistant depression[J]. J Child Psychol Psychiatry, 2020, 61(3): 312-332. doi: 10.1111/jcpp.13202
[40] 刘娜, 李猛, 郜晓辉, 等. 小剂量氨磺必利治疗难治性抑郁症的临床效果[J]. 河南医学研究, 2021, 30(27): 5109-5112. doi: 10.3969/j.issn.1004-437X.2021.27.038 [41] 刘欢乐, 卫拂晓, 秦雪梅, 等. 中西药联合用药抗抑郁研究进展[J]. 中国中药杂志, 2020, 45(16): 3776-3783. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY202016004.htm [42] RAJARATNAM K, XIANG Y T, TRIPATHI A, et al. Clinical use of mood stabilizers with antidepressants in Asia: report from the research on Asian psychotropic prescription patterns for antidepressants (REAP-AD) projects in 2004 and 2013[J]. J Clin Psychopharmacol, 2017, 37(2): 255-259. doi: 10.1097/JCP.0000000000000670
[43] 蔡仲威, 陆奕彬, 唐瑞强, 等. 舍曲林合并碳酸锂治疗青少年情绪障碍临床疗效及分析[J]. 海峡药学, 2021, 33(3): 162-163. doi: 10.3969/j.issn.1006-3765.2021.03.062 [44] CHEN H B, LIN Q W, LIN T, et al. A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: a pilot randomized controlled trial at a single-center in China[J]. J Psychiatr Res, 2019, 114: 133-140. doi: 10.1016/j.jpsychires.2019.04.024
[45] 朱静. 388例儿童青少年抗精神病药物超说明书用药调查[J]. 中国处方药, 2020, 18(8): 45-47. doi: 10.3969/j.issn.1671-945X.2020.08.021 [46] 苑杰, 高静, 肖健, 等. 抗抑郁药物的联合用药研究进展[J]. 中国医药导报, 2017, 14(27): 40-43. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201727011.htm [47] SOLMI M, FORNARO M, OSTINELLI E G, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects[J]. World Psychiatry, 2020, 19(2): 214-232. doi: 10.1002/wps.20765
[48] SAFER D J, ZITO J M. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents[J]. J Child Adolesc Psychopharmacol, 2006, 16(1/2): 159-169.
[49] OLIVA V, LIPPI M, PACI R, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: a systematic review and meta-analysis[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 109: 110266. doi: 10.1016/j.pnpbp.2021.110266
[50] EDINOFF A N, AKULY H A, HANNA T A, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review[J]. Neurol Int, 2021, 13(3): 387-401. doi: 10.3390/neurolint13030038
[51] AMITAI M, CHEN A, WEIZMAN A, et al. SSRI-induced activation syndrome in children and adolescents—what is next[J]. Curr Treat Options Psychiatry, 2015, 2(1): 28-37. doi: 10.1007/s40501-015-0034-9
[52] MENDELSOHN J, COFFEY B J. Serotonin syndrome in an adolescent girl[J]. J Child Adolesc Psychopharmacol, 2019, 29(10): 783-786. doi: 10.1089/cap.2019.29175.bjc
[53] JAHAN S. Can low dose sertraline cause serotonin syndrome in pediatric patients?2 case reports[J]. CNS Spectr, 2021, 26(2): 155.
[54] ZHOU X Y, TENG T, ZHANG Y Q, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis[J]. Lancet Psychiatry, 2020, 7(7): 581-601. doi: 10.1016/S2215-0366(20)30137-1
[55] SHOVAL G, NAHSHONI E, GOTHELF D, et al. Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study[J]. Clin Neuropharmacol, 2011, 34(5): 182-185. doi: 10.1097/WNF.0b013e31822cb863
[56] 宋利利. 青少年抑郁症致病因素及预防措施调查研究[J]. 继续医学教育, 2019, 33(4): 85-86. doi: 10.3969/j.issn.1004-6763.2019.04.047
计量
- 文章访问数:
- HTML全文浏览量:
- PDF下载量:
下载:
苏公网安备 32100302010246号